Bladder cancer is the third most prevalent cancer among men in th USA. Superficial transitional cell carcinomas (TCCs) account for 80-90% of bladder cancers. These TCCs are often multifocal, but are usually not life-threatening. However, ~60% of patients with multiple tumors have recurrences within 4 years, and ~25% of recurrent tumors progress to muscle invasive cancer. An estimated one third of such patients die of bladder cancer in 15-year follow-up studies. Mortality could be reduced if marker(s) were available to predict which superficial TCCs are at highest risk for progression. Unfortunately, the biological significance of genetic alterations in TCCs relative to progression have not been defined. The objective of this proposal is to test a new model for TCC progression. Previous models have focused on p53 alteration as the critical event in progression. New findings suggest that the use of a single genetic marker to predict tumor phenotype is inadequate, rather a phenotype that might require several markers should be evaluated. The research group will test the hypothesis that overcoming the tumor suppressor mechanism of cellular senescence is critical to progression. They will also show that bypassing senescence can be accomplished by several combinations of different genetic alterations.
The Specific Aims to fulfill these goals are: (1) to identify genetic alterations in superficial TCCs and (in a retrospective study) to determine if any genotype present in superficial TCCs has value for predicting progression on recurrence; (2) to determine if superficial TCCs when they progress to muscle invasive TCCs have bypassed senescence; and finally (3) to test if altering p16-mediated senescence growth block by genetic manipulation completes requirements for bypassing senescence in superficial TCCs. The proposed studies are significant because they will lead to a better understanding of bladder cancer pathogenesis. They are also clinically relevant because they may identify useful prognostic markers for TCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA029525-18
Application #
2894528
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Aamodt, Roger L
Project Start
1984-02-01
Project End
1999-10-31
Budget Start
1999-05-01
Budget End
1999-10-31
Support Year
18
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Sarkar, S; Julicher, K P; Burger, M S et al. (2000) Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 60:3862-71
Cuthill, S; Agarwal, P; Sarkar, S et al. (1999) Dominant genetic alterations in immortalization: role for 20q gain. Genes Chromosomes Cancer 26:304-11
Vieten, L; Belair, C D; Savelieva, L et al. (1998) Minimal deletion of 3p13-->14.2 associated with immortalization of human uroepithelial cells. Genes Chromosomes Cancer 21:39-48
Yeager, T R; Reznikoff, C A (1998) Methotrexate resistance in human uroepithelial cells with p53 alterations. J Urol 159:581-5
Savelieva, E; Belair, C D; Newton, M A et al. (1997) 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene 14:551-60
Belair, C D; Yeager, T R; Lopez, P M et al. (1997) Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 94:13677-82
Reznikoff, C A; Belair, C D; Yeager, T R et al. (1996) A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 23:571-84
Reznikoff, C A; Yeager, T R; Belair, C D et al. (1996) Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 56:2886-90
Reznikoff, C A; Belair, C; Savelieva, E et al. (1994) Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev 8:2227-40
Reznikoff, C A; Kao, C; Messing, E M et al. (1993) A molecular genetic model of human bladder carcinogenesis. Semin Cancer Biol 4:143-52

Showing the most recent 10 out of 21 publications